FREEDOM OF INFORMATION SUMMARY

ORIGINAL ABBREVIATED NEW ANIMAL DRUG APPLICATION

ANADA 200-638
IMOXI™ Topical Solution for Cats
(imidacloprid + moxidectin)
Cats

IMOXI™ Topical Solution for Cats is indicated for the prevention of heartworm disease caused by Dirofilaria immitis. IMOXI™ Topical Solution for Cats kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. IMOXI™ Topical Solution for Cats is also indicated for the treatment and control of ear mite (Otodeces cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancylostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxocara cati).

Sponsored by:
Vetoquinol USA, Inc.
Table of Contents

I. GENERAL INFORMATION ....................................................................................... 3
II. BIOEQUIVALENCE .............................................................................................. 4
III. HUMAN FOOD SAFETY ...................................................................................... 4
IV. USER SAFETY ..................................................................................................... 5
V. AGENCY CONCLUSIONS ..................................................................................... 5
I. GENERAL INFORMATION

A. File Number

ANADA 200-638

B. Sponsor

Vetoquinol USA, Inc.
4250 N. Sylvania Ave.
Fort Worth, TX 76137

Drug Labeler Code: 017030

C. Proprietary Name

IMOXI™ Topical Solution for Cats

D. Drug Product Established Name

imidacloprid + moxidectin

E. Pharmacological Category

Antiparasitic

F. Dosage Form

Topical solution

G. Amount of Active Ingredient

100 mg/mL (10%) imidacloprid and 10 mg/mL (1%) moxidectin

H. How Supplied

0.23 mL, 0.4 mL, and 0.8 mL applicator tubes; three 0.23 mL tubes per package, six 0.4 mL tubes per package, and six 0.8 mL tubes per package

I. Dispensing Status

Rx

J. Dosage Regimen

The recommended minimum dose is 4.5 mg/lb. (10.0 mg/kg) imidacloprid and 0.45 mg/lb. (1.0 mg/kg) moxidectin, once a month, by topical administration, as specified in the following table.

<table>
<thead>
<tr>
<th>Cat (lbs)</th>
<th>Volume (mL)</th>
<th>Imidacloprid (mg)</th>
<th>Moxidectin (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-5</td>
<td>0.23</td>
<td>23</td>
<td>2.3</td>
</tr>
<tr>
<td>5.1-9</td>
<td>0.4</td>
<td>40</td>
<td>4</td>
</tr>
<tr>
<td>9.1-18*</td>
<td>0.8</td>
<td>80</td>
<td>8</td>
</tr>
</tbody>
</table>

*Cats over 18 lbs should be treated with the appropriate combination of IMOXI™ Topical Solution for Cats tubes.
K. Route of Administration

Topical

L. Species/Class

Cats

M. Indications

IMOXI™ Topical Solution for Cats is indicated for the prevention of heartworm disease caused by *Dirofilaria immitis*. IMOXI™ Topical Solution for Cats kills adult fleas (*Ctenocephalides felis*) and is indicated for the treatment of flea infestations. IMOXI™ Topical Solution for Cats is also indicated for the treatment and control of ear mite (*Otodectes cynotis*) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (*Ancylostoma tubaeforme*); and adult and fourth stage larvae in roundworms (*Toxocara cati*).

N. Reference Listed New Animal Drug (RLNAD)

Advantage Multi® for Cats; imidacloprid + moxidectin; NADA 141-254; Bayer HealthCare LLC, Animal Health Division

II. BIOEQUIVALENCE

The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Generic Animal Drug and Patent Term Restoration Act (GADPTRA) of 1988, allows for an abbreviated new animal drug application (ANADA) to be submitted for a generic version of an approved new animal drug (RLNAD). The ANADA sponsor is required to show that the generic product is bioequivalent to the RLNAD, which has been shown to be safe and effective. Effectiveness, target animal safety and human food safety data (other than tissue residue data) are not required for approval of an ANADA. If bioequivalence is demonstrated through a clinical endpoint study in a food producing animal, then a tissue residue study to establish the withdrawal period for the generic product is also required. For certain dosage forms, the agency will grant a waiver from the requirement to perform *in vivo* bioequivalence studies (biowaiver) (55 FR 24645, June 18, 1990; Fifth GADPTRA Policy Letter; Bioequivalence Guideline, October 9, 2002).

Based on the formulation characteristics of the generic product, Vetoquinol USA, Inc., was granted a biowaiver for the generic product IMOXI™ Topical Solution for Cats (imidacloprid + moxidectin). The generic product is a topical solution, contains the same active ingredients in the same concentrations and dosage form as the RLNAD, and contains no inactive ingredients that may significantly affect the bioavailability of the active ingredient. The RLNAD is Advantage Multi® for Cats (imidacloprid + moxidectin) topical solution, sponsored by Bayer HealthCare LLC, Animal Health Division, under NADA 141-254, and was approved for use in cats on January 19, 2007.

III. HUMAN FOOD SAFETY

This drug is intended for use in cats. Because this new animal drug is not intended for use in food producing animals, CVM did not require data pertaining to drug residues in food (i.e., human food safety) for approval of this ANADA.
IV. USER SAFETY

The product labeling contains the following information regarding safety to humans handling, administering, or exposed to IMOXI™ Topical Solution for Cats:

**Not for human use. Keep out of the reach of children. Children should not come in contact with application sites for 30 minutes after application.**

Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing. Avoid contact with skin. Exposure to the product has been reported to cause headache; dizziness; and redness, burning, tingling, or numbness of the skin.

**Wash hands thoroughly with soap and warm water after handling.**

If contact with eyes occurs, hold eyelids open and flush with copious amounts of water for 15 minutes. If eye irritation develops or persists, contact a physician. If swallowed, call poison control center or physician immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or physician. People with known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution. In case of allergic reaction, contact a physician. If contact with skin or clothing occurs, take off contaminated clothing. Wash skin immediately with plenty of soap and water. Call a poison control center or physician for treatment advice.

The Safety Data Sheet (SDS) provides additional occupational safety information. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Vetoquinol USA at 1-800-835-9496 or www.vetoquinolusa.com.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

V. AGENCY CONCLUSIONS

This information submitted in support of this ANADA satisfies the requirements of section 512(c)(2) of the Federal Food, Drug, and Cosmetic Act. The data demonstrate that IMOXI™ Topical Solution for Cats when used according to the label, is safe and effective.